Transcranial Magnetic Stimulation

FDA-cleared for the treatment of depression, the EXOMIND’s patented ExoTMS™ technology comfortably stimulates key areas of the brain involved in emotional regulation, cognitive function, and self-control. TMS harnesses the brain’s natural neuroplasticity to support lasting wellness and mental health, offering a safe, effective option for those seeking innovative solutions for psychiatric conditions and overall well-being.

Why TMS?

  • ✺

    Enhance Cognitive Precision and Emotional Resilience

    TMS supports improved mood regulation and mental clarity, helping top performers stay focused under high-pressure demands.

  • ✺

    Non-Disruptive, Drug-Free Treatment

    With no systemic side effects and minimal downtime, TMS fits seamlessly into the schedules of executives, physicians, entrepreneurs, and other driven professionals.

  • ✺

    Sustain Peak Performance and Well-Being

    Many high-functioning individuals experience better concentration, improved decision-making capacity, and restored motivation through a structured, evidence-based TMS program.

✺ Frequently asked questions ✺

  • TMS is FDA-cleared for treatment-resistant major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and nicotine dependence. It is most commonly used for adults who have not responded to at least one or two adequate antidepressant trials. There is also emerging evidence for its use in bipolar depression, post-traumatic stress disorder (PTSD), and substance use disorders

  • While traditional TMS for depression typically requires 20 to 36 sessions (five days a week for 4-6 weeks), an Exomind treatment plan for depression often involves around 6 sessions, though some treatment plans may extend to 20 or 30 sessions depending on the patient's specific condition and goals

  • TMS is generally well tolerated. The most common side effects are headache and scalp discomfort, followed by fatigue, pain, dizziness, insomnia, and mild eye or nasal symptoms. Serious adverse events, such as seizures, are rare and usually occur in patients with predisposing factors. There is no evidence that TMS induces hypomania in unipolar depression, but affective switches may occur in bipolar disorder

  • Predictors of favorable response include lower age, lower degree of treatment resistance, absence of comorbid anxiety or psychotic symptoms, and female sex. Maintenance TMS and combination with other therapies may improve durability of response. Incomplete initial response and comorbid anxiety are associated with higher relapse rates after TMS